Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00829673 |
Recruitment Status
:
Completed
First Posted
: January 27, 2009
Results First Posted
: August 4, 2009
Last Update Posted
: August 19, 2009
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Dexmethylphenidate Hydrochloride | Phase 1 |
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Dexmethylphenidate Hydrochloride, (10 mg), Compared to an Equivalent Dose of a Commercially Available Reference Product (Focalin®, Novartis Pharmaceuticals Corporation) in 24 Fed, Healthy, Adult Subjects |
Study Start Date : | June 2004 |
Actual Primary Completion Date : | June 2004 |
Actual Study Completion Date : | June 2004 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Drug: Dexmethylphenidate Hydrochloride
10 mg Tablet
|
Active Comparator: 2
Focalin®
|
Drug: Dexmethylphenidate Hydrochloride
10 mg Tablet
Other Name: Focalin®
|
- Cmax (Maximum Observed Concentration) [ Time Frame: Blood samples collected over a 16 hour period. ]
- AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) [ Time Frame: Blood samples collected over a 16 hour period. ]
- AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) [ Time Frame: Blood samples collected over a 16 hour period. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
- Sex: Male and Female; similar proportion of each preferred.
- Age: At least 18 years.
- Weight: BMI (Body Mass Index) less than or equal to 30.
-
Qualifying subjects must be in good health and physical condition as determined by medical history, complete physical examination, and laboratory tests, all obtained within four (4) weeks prior to study start. The subjects may not have a history of significant past illness expected to affect the investigation. The normal status of subjects will be confirmed by the following procedures:
- Laboratory Tests: Hemoglobin, hematocrit, RBC, WBC, differential count, serum electrolytes (Na, K, Cl), fasting blood glucose, BUN, bilirubin,m creatinine, AST, ALT, LD, alkaline phosphatase and urinalysis. HIV, Hepatitis B, Hepatitis C, breath alcohol test, and drugs of abuse testing will be done for screening purposes only. Urine drugs of abuse testing and breath alcohol testing will be repeated at each check-in. Female subjects will have a serum pregnancy test done at screening and a urine pregnancy test prior to each study period at check-in.
Laboratory values which are greater than ±20% of the normal range will not qualify unless specifically accepted (with comment) by the Principal Investigator. Results of HIV, Hepatitis B, Hepatitis C, and drugs of abuse must be negative or non-reactive for the subject to qualify for the study.
- Electrocardiogram: A 12-lead electrocardiogram (ECG) will be obtained for all subjects. The original tracings, plus interpretation, will be included in the case report form packet.
- Subjects must read and sign the Consent Form.
Exclusion Criteria
- Subjects not complying with the above inclusion criteria must be excluded from the study.
-
In addition, any one of the conditions listed below will exclude a subject from the study:
- History of treatment for alcoholism, substance abuse, or drug abuse within past 24 months.
- History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
- History of GERD (gastroesophageal reflux disease), stricture of the esophagus, achalasia, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease.
- History of upper gastrointestinal disorder such as dysphagia, esophagitis, gastritis, ulcers.
- History of treatment for asthma within the past five (5) years.
- History of marked treatable anxiety, tension, agitation.
- History of glaucoma
- History of motor tics
- Family history or diagnosis of tourettes syndrome
- History of treatment with monoamine oxidase inhibitors
- History of seizures
- Inability to sit upright for a period of at least 30 minutes
- Females who are pregnant or lactating
- History of hypersensitivity to dexmethylphenidate hydrochloride, methylphenidate or any central nervous system stimulant
-
Conditions upon screening which might contraindicate or require that caution be used in the administration of dexmethylphenidate hydrochloride, including:
- Sitting systolic blood pressure below 90 mm Hg, or diastolic pressure below 50 mm Hg.
- Heart rate less than 50 beats per minute after a 5-minute rest in a seated position.
- Inability to read and/or sign the consent form.
- Treatment with any other investigational drug during the four (4) weeks prior to the initial dosing for this study.
- Subjects who have donated blood within four (4) weeks prior to the initial dosing for this study.
- Subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.). Three (3) months abstinence is required.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00829673
United States, Missouri | |
Gateway Medical Research, Inc. | |
St. Charles, Missouri, United States, 63301 |
Principal Investigator: | Irwin Plisco, M.D. | Cetero Research, San Antonio |
ClinicalTrials.gov Identifier: | NCT00829673 History of Changes |
Other Study ID Numbers: |
04163 |
First Posted: | January 27, 2009 Key Record Dates |
Results First Posted: | August 4, 2009 |
Last Update Posted: | August 19, 2009 |
Last Verified: | August 2009 |
Keywords provided by Teva Pharmaceuticals USA:
Bioequivalence Healthy Subjects |
Additional relevant MeSH terms:
Dexmethylphenidate Hydrochloride Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents |